Skip to main content

International Psoriasis Council

Advancing Knowledge. Improving Care.

Hervé Bachelez Headshot

Hervé

Bachelez

,

MD, PhD

Professor
Hôpital Saint-Louis, Imagine Institute for Human Genetic Diseases, Paris Cité University
Paris
,
France
Councilor Since: May 1, 2009
IPC Councilor
Professor Hervé Bachelez is a professor at the Department of Dermatology of the Saint-Louis University Hospital in Paris, France. Since 2004, Professor Bachelez has been a Full Professor of Clinical Dermatology at the Université Paris-Diderot/Université de Paris, where he received his PhD in Immunology in 1999. Professor Bachelez’s clinical and research activities focus on inflammatory skin diseases, mainly psoriasis and psoriasis-related diseases, hidradenitis suppurativa, and lichen planus. He is conducting his basic and translational research at the Institut National de la Santé et de la Recherche Médicale (INSERM U1163) in the Laboratory of Genetics of Skin Diseases at the Imagine Institute for Human Genetic Diseases in Necker Hospital, Paris. His areas of scientific research include immunogenetics and molecular mechanisms of the aforementioned immune-mediated and inflammatory skin diseases. Professor Bachelez has received several scientific awards, including the Robert Degos Award. He is a member of several national and international scientific societies, including the European Academy of Dermatology and Venereology (EADV) and the European Dermatology Forum (EDF). He is the past president of the French Society for Dermatological Research and the Group for Research on Psoriasis of the French Society for Dermatology. Internationally, he is a Board Member of the International Psoriasis Council (IPC) and the past president of the European Society for Dermatological Research (ESDR). Professor Bachelez has published over 295 manuscripts in peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Investigation, the Lancet, and Arthritis and Rheumatism as a leading author.

He previously served on the IPC Board of Directors from 2010 to 2025, and was IPC President from 2022 – 2024.
Last Updated:
01/09/2024

Areas of Interest

Immunopathology and immunogenetics, translational research, and clinical trials.

IPC Committees / Groups

Emerging Infectious Diseases Task Force, Executive Committee, Finance Committee, Research Committee

Languages Spoken

English, French

Involvement with Other Organization(s)

Professor Bachelez serves on the Scientific Board of the French Psoriasis Group (GRPSO) and is a reviewer for the Swiss National Research Fund, Medical Research Council, and French National Research Agency (ANR).

What's New

Global and Collaborative Research in Psoriasis: IPC Fellows Research Class #1 Recordings

Recordings from the IPC Fellows Research Class #1: Global and Collaborative Research in Psoriasis are now available. Program Chairs Peter van de Kerkhof, MD, PhD, and María Julia Cura, MD, led a faculty of international experts through sessions on unresolved questions in the era of effective psoriasis therapies, building global research collaborations, and connecting psoriasis research across disciplines. Watch to hear from Wolf Henning Boehncke, MD, MA, Christopher Griffiths, OBE, MD, FMedSci, and Georg Stingl, MD, as they share perspectives shaping the next generation of psoriasis research.

WATCH NOW

Wednesday, July 15, 2026

New in the IPC Resource Library: Research Skills

The IPC Resource Library now includes a dedicated Research Skills category, bringing together videos, articles, and presentations focused on building stronger research capabilities in psoriasis. Browse the current collection to find resources on topics from collaborative research methods to career development for researchers at every stage.

WATCH NOW

Thursday, July 13, 2026

New Take Tens on Psoriatic Arthritis

IPC Councilor Anna Lopez Ferrer, MD, PhD, reviews PURE-4, a four-item tool that helps dermatologists screen psoriasis patients for psoriatic arthritis (PsA) risk. She traces its evolution across three studies (2018–2026) into a validated predictor of early PsA.

IPC Councilor André Lucas Ribeiro, MD, reframes PsA as a slow transition from psoriasis, not a sudden event, opening the door to disease interception. He outlines the steps needed to get there, from harmonizing definitions to reducing inflammatory burden.

WATCH NOW

Wednesday, July 8, 2026